Szanowni Państwo,

jest nam niezmiernie miło poinformować, że do naszego Przewodnika dołączyła kolejna ankieta ewaluacyjna. Dotyczy ona świerzbiączki guzkowej.

Świerzbiączka guzkowa jest dermatozą, która objawia się występowaniem swędzących guzków skórnych. Guzki pojawiają się jako odpowiedź na nadmierne drapanie lub uszkodzenie skóry. Często więc schorzenie to towarzyszy innym chorobom, w przebiegu których występuje uporczywy świąd, takim jak liszaj płaski, pemfigoid pęcherzowy, atopowe zapalenie skóry, kontaktowe zapalenie skóry czy świerzb. Świerzbiączka jest więc chorobą, która przez swoje uporczywe dolegliwości, wpływa na jakość życia, snu czy relacji towarzyskich osób, które dotyka.

Ankieta dostępna w naszym przewodniku zawiera 3 badania kliniczne poszukujące uczestników na terenie Polski.

Zachęcamy do zapoznania się z zawartościąankiety.



Szanowni Państwo,

jest nam niezmiernie miło poinformować, że do naszego Przewodnika dołączyła kolejna ankieta ewaluacyjna. Dotyczy ona świerzbiączki guzkowej.

Świerzbiączka guzkowa jest dermatozą, k...

Nowa ankieta - świerzbiączka guzkowa

#### W dniu 23.10.2019 r. sfinalizowano kolejną aktualizację przewodnika po badaniach klinicznychBadX.  
  
Poniższa tabela zawiera listę badań klinicznych, które zostały zakończone bądź zamknęły proces rekrutacji (usunięto*) oraz nowe badania, które pojawiły się właśnie na rynku (dodano*).  
  
Lista wprowadzonych zmian jest następująca:
*Astma:*  
***Dodano:***  
-**GB001 (**GB001 in Adult Subjects With Moderate to Severe Asthma)  
-**AAPABA**(Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis)  
-**MTPS9579A**(A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller)  
***Usunięto:***  
*-*****QMF149vTwisthaler**(Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma)  
**-MiSEAP**(Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients)  
**-DESTINATION**(Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma)  
**-RAISe**(Response of the Airway in Sinusitis and Asthma)  
**-PATH-HOME**(Tezepelumab Home Use Study)  
**-MDL AZD7594 (**A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects)  
**-VOYAGE**(Evaluation of Dupilumab in Children With Uncontrolled Asthma)*Atopowe zapalenie skóry:*  
***Dodano:***  
-**JADE TEEN**(JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis)  
-**NemoAtD 2**(Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis)  
***Usunięto:***  
-**BREEZE-AD4**(A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable)  
-**BREEZE-AD7**(A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis)  
-**JADE Mono-2**(Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis)*Choroba Alzheimera:*  
***Dodano:***  
-**GAIN**(GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease)  
-**RO7105705**(A Study of RO7105705 in Patients With Moderate Alzheimer's Disease)  
***Usunięto:***  
-**BI 425809**(BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease)  
-**COGNITE**(Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease)  
-**MissionAD1**(A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease)  
-**MissionAD2**(A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease)  
-**PimaDemPsy**(Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis)  
-**TANGO**(Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease)*Choroba Leśniowskiego-Crohna:*  
***Dodano:***  
**-PRISM**​​​​​​ (A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease)  
-**SHR0302 CD**(A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease)  
-**E6011 CD**(A Study of E6011 in Participants With Active Crohn's Disease)  
***Usunięto:***  
-**EtroPedCD**(A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease)*Choroba zwyrodnieniowa stawów:*  
***Dodano:***  
**-FasinumabOsteo**(Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee)  
***Usunięto:***  
-**FACT LTS & OA**(Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip)*Cukrzyca:*  
***Dodano:***  
-**ProGasMet**(Probiotics in Metformin Intolerant Patients With Type 2 Diabetes)  
-**SUSTAIN FORTE**(A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes)  
-**SURPASS-5**(A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin)  
-**FLOW Db**(A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease)  
-**Granexin**(A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer)  
-**RedStroke Db**(RedStroke - Reducing Europe's Stroke Incidence)  
**-GRACE Db**(A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome)  
***Usunięto:***  
-**AMPLITUDE-M**(Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise)  
-**287/Glarg**(A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before)  
-**Insulin 287**(A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes)  
-**PRO Solo**(Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System)*Jaskra:*  
***Dodano:***  
-**BimaSR/Laser**(Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension)*Migotanie przedsionków:*  
***Dodano:***  
-**ENVISAGE-TAVI AF**(Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation)  
-**Watchman FLX (Eur)**(Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only))  
-**ASAP-TOO**(Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation)*Nadciśnienie płucne:*  
***Dodano:***  
-**EXPERT-BPA**(Hemodynamic Effects of BPA at Rest and During Exercise in CTEPH)  
-**SELECT PH**(A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery)  
-**RaliPH**(A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients)  
***Usunięto:***  
-**InShape2**(Early Non-invasive Detection of CTEPH After Pulmonary Embolism)  
-**REPLACE**(Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy)*Nadciśnienie tętnicze:*  
***Usunięto:***  
-**ASSECURE**(Cardiovascular Response to Exercise in Hypertension)  
-**Moderato**(Moderato System in Patients With Hypertension)  
-**ModeratoV.1.1**(Moderato System: A Double-Blind Randomized Trial Ver 1.1)  
-**PRECIOUS**(Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine)*Niealkoholowa stłuszczeniowa choroba wątroby:*  
***Usunięto:***  
-**Kids4LIFe**(Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI)  
-**REGENERATE**(Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment)*Otyłość:*  
***Usunięto:***  
-**MicroPCOS**(Effect of Dietary Modifacation on Microbiota in Overweight and Obese Polycystic Ovary Syndrome Patients)  
-**ProSupp**​​​​​ (Effect of Oral Supplementation With Probiotics)*Przewlekła choroba nerek:*  
***Usunięto:***  
-******ASCEND-ID**(Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis)  
-**Dapa-CKD**​​​​​ (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease)  
-**KALM-2**(CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus)  
-**PRO2TECT**(Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))*Rak jelita grubego:*  
***Dodano:***  
-**SOLSTICE**(Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy)  
-**PIPACRegis**(International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC))*RZS:*  
***Usunięto:***  
-**TvTNF**(Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis)*Stwardnienie rozsiane:*  
***Dodano:***  
-**EVOLUTION RMS1**(Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS))  
-**O'HAND**(A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis)  
***Usunięto:***  
-**ASCLEPIOS II**(Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis)  
-**CLARIFY MS**(Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS))  
-**EVOLVE-MS-1**(A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS))  
-**HAMS**(Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS))  
-**OPTIMUM-LT**(Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis)*Toczeń rumieniowaty układowy:*  
***Dodano:***  
-**VIB-SLE**(A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis)  
***Usunięto:***  
-******BI 655064 SLE**(Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis)  
-**CC-220 SLE**(A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus)  
-**M2951 II**(A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE))  
-**TULIP-LN1**(Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis)*Wrzodziejące zapalenie jelita grubego:*  
***Dodano:***  
-**GSK2831781 UC**(Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis)  
-**QUASAR**(A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis)  
***Usunięto:***  
-**CONDUCT**(The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis)

W dniu 23.10.2019 r. sfinalizowano kolejną aktualizację przewodnika po badaniach klinicznych BadX.

Poniższa tabela zawiera listę badań klinicznych, które zostały zakończone bądź zamknęły proces rekru...

32 NOWE BADANIA KLINICZNE - aktualizacja z dnia 23.10.2019

#### W dniu 16.02.2020 r. sfinalizowano kolejną aktualizację przewodnika po badaniach klinicznych*BadX*.  
  
Poniższa tabela zawiera listę badań klinicznych, które zostały zakończone bądź zamknęły proces rekrutacji (usunięto*) oraz nowe badania, które pojawiły się na rynku (dodano*).  
  
Lista wprowadzonych zmian jest następująca:
*Astma:*

***Dodano:***  
**OpInh**(Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma)  
**Inhtech**(Factors Influencing on Correctness of Inhalation Technique.)  
**THUNDER**(Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma)  
**MATIC**(Mite Allergy Trial In Children)



***Usunięto:***  
**QMF149**(A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma)  
**MRx-4DP0004**(A Study of MRx-4DP0004 in Asthma)  
**PONENTE**(Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma)  
**SOURCE**(Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma)  
**FlutFuro**(Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year)  
**BIOSAMOT**(BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment)

*Atopowe zapalenie skóry:*  
  
***Dodano:***  
**PF-067 AtD**(Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis)  
**UpaAtD**(Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis)  
**MEDI3506 AtD**(Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis)  
**REGN3500 AtD 2 (Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis)**  
**REGN3500 AtD**(Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis)  
  
***Usunięto:***  
**ECZTRA 6**(Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis)  
**ECZTRA 7**(Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A)  
**GUANA**(A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis)  
**JADE Compare**(Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy)  
**MSTT1041A**(A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis)  
**PF-04965842 AtD**(Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects)  
**WBCryo**(Assessment of the Impact of Whole Body Cryostimulation on Skin Physiological Indicators)*Choroba Alzheimera:*  
  
***Dodano:***  
**AVP-786 Alz**(Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type)*Choroba Leśniowskiego-Crohna:*  
  
***Dodano:***  
**GIANT**(Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease)  
  
***Usunięto:***  
**SEAVUE**(Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year)*Choroba zwyrodnieniowa stawów:*  
  
***Dodano:***  
**MONOVISC Ankle**(MONOVISC for Ankle Joint Pain Relief)  
**MONOVISC Shoulder**(MONOVISC for Shoulder Joint Pain Relief)  
**MONOVISC Hip**(MONOVISC for Hip Joint Pain Relief)  
**REGN5069**(A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee)  
  
***Usunięto:***  
**FasinumabOsteo**(Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee)*Cukrzyca:*  
  
***Dodano:***  
**PROTECT**(Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab)  
**PF-06882961 Db**(A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus)  
**MEDI7352 Db**(Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy)  
**BLOSSOM (**Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life)  
  
***Usunięto:***  
**GLITTER 1**(Gan & Lee Insulin Glargine Target Type (1) Evaluating Research)  
**AMPLITUDE-D**(Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin)  
**SCORED**(Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk)  
**SUSTAIN 11**(A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes)  
**SUSTAIN FORTE**(A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes)*Jaskra:*  
  
***Dodano:***  
**BimaSRGlauc**(Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension)  
  
***Usunięto:***  
**Bimatoprost SR**(Long-term Safety and Efficacy Extension Trial of Bimatoprost SR)*Łuszczyca i łuszczycowe zapalenie stawów:*  
  
***Dodano:***  
**PF-06700841 PsO**(Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis)  
**PF-06826647**(A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis)  
**SecuExt**(An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA))  
  
***Usunięto:***  
**BMS-986165 PsA**(Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA))  
**COSMOS**(A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy)  
**HaloFoam**(Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis)  
**IMMpact2**(A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies))  
**VOLTAIRE-X**(The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis.)*Migotanie przedsionków:*  
  
***Dodano:***  
**HighRF-AF**(High RF Energy Ablation of Atrial Fibrillation)*Nadciśnienie płucne:*  
  
***Dodano:***  
**A DUE**(Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH))  
**SelexiPedPH Add-on**(A Study of as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension)  
  
***Usunięto:***  
**PATENT-CHILD**(Riociguat in Children With Pulmonary Arterial Hypertension (PAH))*Niealkoholowa stłuszczeniowa choroba wątroby:*  
  
***Dodano:***  
**CC-90001 NAFLD**(Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis)  
  
***Usunięto:***  
**NATIVE**(Phase 2b Study in NASH to Assess IVA337)*Otyłość:*  
  
***Dodano:***  
**6-10-14**(Community Based Obesity Prevention and Treatment Programme "6-10-14 for Health")  
**WELCOME**(Diet for the Maintenance of Weight Loss and Metabolic Health in Obese Postmenopausal Women)  
  
***Usunięto:***  
**NNC0174-0833**(Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.)*Przewlekła choroba nerek:*  
  
***Dodano:***  
**Dapa-CKD**(A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease)  
**HAV PChN**(Safety and Efficacy Assessment of HAV (Manufactured Using Large-scale System) in Patients Needing Vascular Access for Dialysis)  
**KALM**(CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus)  
**KALM-2**(CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus)  
  
***Usunięto:***  
**ASCEND-NHQ**(Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life)  
**SCORED PChN**(Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk)*Rak jelita grubego:*  
  
***Dodano:***  
**MycoCRC**(Mycotoxin Exposure and Dietary Habits in Colorectal Cancer Prevention and Development Among Polish Population)  
**RomiTrhomb**(Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer)  
**PIVOT-02 CRC**(A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors)  
  
***Usunięto:***  
**PRECONNECT**(A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).)*Reumatoidalne zapalenie stawów:*  
  
***Dodano:***  
**CT-P17 A-i**(A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis)  
**ABX464 2 RZS**(Study Evaluating the One-Year Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis)  
**SKI-O-703 RZS**(A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.)  
**ABX464 RZS**(Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis)  
**PF-064vHumira**(A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis)  
**MANTA-RAy RZS**(Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis)  
**BraneRZS**(Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis)  
  
***Usunięto:***  
**ABBV-599 Comb**(A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.)  
**AMG 592**(Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis)  
**JHL1101**(A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis)*Stwardnienie rozsiane:*  
  
***Dodano:***  
**NBSS&Quali PL**(Polish Translation and Validation of NBSS, Qualiveen and SF-Qualiveen)  
**OcrePed SM**(A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis)  
**Antelope**(Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®)  
  
***Usunięto:*  
CONSONANCE**(A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis)  
**OcreMS**(Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS))  
**POINT**(Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate)*Toczeń rumieniowaty układowy:*  
  
***Dodano:***  
**PF-06700841 SLE**(A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE))  
**BraneSLE**(Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis)  
**ObiSLE**(A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis)*Wrzodziejące zapalenie jelita grubego:*  
  
***Dodano:***  
**ABX464**(Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis)  
**ELEVATE UC 52**(Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis)  
**Oral BT-11 UC**(Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis)  
  
***Usunięto:***  
**Etro vs Ada #1**(A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1))  
**Etro vs Ada #2**(A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2))  
**OCTAVE2**(A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission)

W dniu 16.02.2020 r. sfinalizowano kolejną aktualizację przewodnika po badaniach klinicznych BadX.

Poniższa tabela zawiera listę badań klinicznych, które zostały zakończone bądź zamknęły proces rekru...

52 NOWE BADANIA KLINICZNE - aktualizacja z dnia 16.02.2020 r.

W dniu dzisiejszym oddajemy do Państwa dyspozycji 9 nowych ankiet ewaluacyjnych. Opublikowane ankiety dotyczą następujących chorób hematoonkologicznych: ostra białaczka szpikowa (AML), ostra białaczka limfoblastyczna (ALL), przewlekła białaczka szpikowa (CML), przewlekła białaczka mielomonocytowa (CMML), zespół mielodysplastyczny szpiku (MDS), czerwienica prawdziwa (PV), nadpłytkowość samoistna (ET), pierwotne włóknienie szpiku (PMF) oraz mastocytoza.



W dniu dzisiejszym oddajemy do Państwa dyspozycji 9 nowych ankiet ewaluacyjnych. Opublikowane ankiety dotyczą następujących chorób hematoonkologicznych: ostra białaczka szpikowa (AML), ostra białaczka...

Nowe ankiety ewaluacyjne z zakresu hematoonkologii

### Udało się wyeliminować problem z rejestracją użytkownika.
### Na niektórych telefonach rejestracja kończyła się niepowodzeniem.
### Aktualizacja oprogramowania usunęła ten błąd.
### Zachęcamy do rejestracji w Przewodniku po Badaniach Klinicznych.
System powinien działać prawidłowo na wszystkich telefonach.

Przepraszamy za kłopot.

W przypadku jakichkolwiek problemów lub uwag prosimy o kontakt.

mail: badania@badx.pl

tel. 506 196 888



Udało się wyeliminować problem z rejestracją użytkownika.

Na niektórych telefonach rejestracja kończyła się niepowodzeniem.

Aktualizacja oprogramowania usunęła ten błąd.

Zachęcamy do rejestracji w ...

Usunięto błąd rejestracji z telefonu

Usunięto błąd rejestracji na telefonie

W dniu dzisiejszym rozszerzono bibliotekę ankiet ewaluacyjnych do badań klinicznych**BadX**o nową chorobę -***RAKA JELITA GRUBEGO**.*  
  
Ankieta zawiera informacje o wszystkich badaniach klinicznych dotyczących tej choroby, prowadzących rekrutację na terenie naszego kraju.

### 


W dniu dzisiejszym rozszerzono bibliotekę ankiet ewaluacyjnych do badań klinicznych BadX o nową chorobę - RAKA JELITA GRUBEGO. 

Ankieta zawiera informacje o wszystkich badaniach klinicznych dotyczący...

RAK JELITA GRUBEGO - nowa ankieta ewaluacyjna

W dniu dzisiejszym opublikowane zostały cztery nowe ankiety ewaluacyjne do badań klinicznych***BadX.***Dotyczą one następujących chorób:**r****ak pęcherza moczowego,****rak prostaty**,**rak szyjki macicy**oraz**rak żołądka**.  
  
Ankiety zawierają informacje o wszystkich badaniach klinicznych dotyczących tych chorób, prowadzących aktualnie rekrutację na terenie naszego kraju.



W dniu dzisiejszym opublikowane zostały cztery nowe ankiety ewaluacyjne do badań klinicznych BadX. Dotyczą one następujących chorób: rak pęcherza moczowego, rak prostaty, rak szyjki macicy oraz rak żo...

4 nowe ankiety ewaluacyjne

W dniu dzisiejszym opublikowane zostały dwie nowe ankiety ewaluacyjne do badań klinicznych***BadX***-**CZERNIAK**oraz***RAK PIERSI**.*  
  
Ankiety zawierają informacje o wszystkich badaniach klinicznych dotyczących tych chorób, prowadzących aktualnie rekrutację na terenie naszego kraju.

Pragniemy również poinformować, że w najbliższym czasie do naszej biblioteki dołączą trzy nowe ankiety ewaluacyjne, dotyczące: raka żołądka, raka pęcherza moczowego oraz raka prostaty.



W dniu dzisiejszym opublikowane zostały dwie nowe ankiety ewaluacyjne do badań klinicznych BadX - CZERNIAK oraz RAK PIERSI. 

Ankiety zawierają informacje o wszystkich badaniach klinicznych dotyczącyc...

CZERNIAK i RAK PIERSI - nowe ankiety ewaluacyjne

W dniu 1.08.2019 r. sfinalizowano aktualizację listy badań klinicznych w poszczególnych ankietach ewaluacyjnych, dodając oraz usuwając następujące badania:*Atopowe zapalenie skóry:*  
***Dodano:***  
-**CrisaboroleAtD**(A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD)  
-**JADE EXTEND**(Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis)  
-**TezapeAtD**(A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis)  
-**NemoliAtD**(Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis)*Przewlekła choroba nerek:*  
***Dodano:***  
-**SAPPHIRE**(A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia)  
-**FERUXIDA**(A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD))  
-**VALOR-CKD**(Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis)  
-**PRO2TECT**(Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))  
-**PRO2TECT.2**(Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))  
-**KALM-2**(CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus)*Reumatoidalne zapalenie stawów:*  
***Dodano:***  
-**ABBV105/599**(A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.)  
-**RA-BRIDGE**(A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis)  
***Usunięto:***  
*-***FINCH IV**(Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis)  
-**EVO**(Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis)Stwardnienie rozsiane:  
***Dodano:**  
-***OfatSM**(Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS)  
***Usunięto:***  
*-***EVOLVE-MS-2**(A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis)Toczeń rumieniowaty układowy:  
***Dodano:**  
-*******LT****BMS-986165 SLE**(Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus)  
-**ABBV-105&Upa**(A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus)  
*-***VAY736 & CFZ533 SLE**(Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients)  
-**BMS-986165 LupNephr**(An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis)  
***Usunięto:***  
**-LILAC (**Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus)Wrzodziejące zapalenie jelita grubego:  
***Dodano:***  
-**ABX464 2b**(Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis)  
-**BMS-986165 UC**(Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC))  
-**RHEA**(Efficacy & Safety of TD-1473 in Ulcerative Colitis)  
-**TD-1473 UC**(Efficacy & Safety of TD-1473 in Ulcerative Colitis)  
-**SHR0302 UC**(A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis)  
-**ST-0529 UC**(A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis)  
***Usunięto:***  
-**AiPSwMtSUC**(Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis)  
-**EtroPedUC**(A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease)

W dniu 1.08.2019 r. sfinalizowano aktualizację listy badań klinicznych w poszczególnych ankietach ewaluacyjnych, dodając oraz usuwając następujące badania: 

Atopowe zapalenie skóry:
Dodano: 
- Crisab...

Aktualności

Wiadomości na temat badań klinicznych oraz ankiet BadX!